These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30099124)

  • 1. New leads for drug repurposing against malaria.
    Pazhayam NM; Chhibber-Goel J; Sharma A
    Drug Discov Today; 2019 Jan; 24(1):263-271. PubMed ID: 30099124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.
    Mogire RM; Akala HM; Macharia RW; Juma DW; Cheruiyot AC; Andagalu B; Brown ML; El-Shemy HA; Nyanjom SG
    PLoS One; 2017; 12(10):e0186364. PubMed ID: 29088219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing drugs to target the malaria parasite unfolding protein response.
    Chen Y; Murillo-Solano C; Kirkpatrick MG; Antoshchenko T; Park HW; Pizarro JC
    Sci Rep; 2018 Jul; 8(1):10333. PubMed ID: 29985421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring anti-malarial potential of FDA approved drugs: an in silico approach.
    Ramakrishnan G; Chandra N; Srinivasan N
    Malar J; 2017 Jul; 16(1):290. PubMed ID: 28720135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
    Ellekvist P; Colding H
    Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating multidrug-resistant Plasmodium falciparum malaria.
    Thu AM; Phyo AP; Landier J; Parker DM; Nosten FH
    FEBS J; 2017 Aug; 284(16):2569-2578. PubMed ID: 28580606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
    Deniskin R; Frame IJ; Sosa Y; Akabas MH
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repositioning in the treatment of malaria and TB.
    Nzila A; Ma Z; Chibale K
    Future Med Chem; 2011 Sep; 3(11):1413-26. PubMed ID: 21879845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action.
    Pessanha de Carvalho L; Kreidenweiss A; Held J
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.
    Aponte S; Guerra ÁP; Álvarez-Larrotta C; Bernal SD; Restrepo C; González C; Yasnot MF; Knudson-Ospina A
    Trans R Soc Trop Med Hyg; 2017 Feb; 111(2):71-80. PubMed ID: 28460112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Drugs to Fight Hepatic Malaria Parasites.
    Fontinha D; Moules I; Prudêncio M
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32731386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commercial drugs containing flavonoids are active in mice with malaria and in vitro against chloroquine-resistant Plasmodium falciparum.
    Penna-Coutinho J; Aguiar AC; Krettli/ AU
    Mem Inst Oswaldo Cruz; 2018 Dec; 113(12):e180279. PubMed ID: 30540020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium chloroquine resistance and the search for a replacement antimalarial drug.
    Wellems TE
    Science; 2002 Oct; 298(5591):124-6. PubMed ID: 12364789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel compounds and repurposing of FDA drugs for 1-deoxy-D-xylulose 5-phosphate reductoisomerase enzyme of Plasmodium falciparum to combat malaria resistance.
    Aziz S; Waqas M; Naz HF; Halim SA; Jan A; Muhsinah AB; Khan A; Al-Harrasi A
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128672. PubMed ID: 38092105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs.
    Kitchen LW; Vaughn DW; Skillman DR
    Clin Infect Dis; 2006 Jul; 43(1):67-71. PubMed ID: 16758420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
    Madhav H; Hoda N
    Eur J Med Chem; 2021 Jan; 210():112955. PubMed ID: 33131885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.
    Reungprapavut S; Krungkrai SR; Krungkrai J
    J Enzyme Inhib Med Chem; 2004 Jun; 19(3):249-56. PubMed ID: 15499996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant Plasmodium falciparum chloroquine resistance transporter in Hodeidah, Yemen: association with parasitologic indices and treatment-seeking behaviors.
    Abdul-Ghani R; Farag HF; Allam AF; Shawky SM; Al-Mekhlafi AM
    Acta Trop; 2013 Dec; 128(3):473-8. PubMed ID: 23906615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule inhibitors as a potential treatment for malaria.
    Kappes B; Rohrbach P
    Future Microbiol; 2007 Aug; 2(4):409-23. PubMed ID: 17683277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.
    Lucchi NW; Komino F; Okoth SA; Goldman I; Onyona P; Wiegand RE; Juma E; Shi YP; Barnwell JW; Udhayakumar V; Kariuki S
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7540-7. PubMed ID: 26392510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.